Volition Appoints Timothy I. Still as Chairman
VolitionRx (NYSE AMERICAN: VNRX) has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Still brings over 35 years of experience in medical diagnostics, devices, and digital health. He previously served as President and CEO of Sense Biodetection and held leadership positions at various medical technology companies. His most recent role was at TSTILL Enterprises as Chairman and CEO, while also serving as an Operating Partner with REVIVAL Healthcare. Still holds an MBA from USC and a BS from UC Davis. The appointment comes at what the company describes as a pivotal time in its development of epigenetic technology for disease detection and monitoring.
VolitionRx (NYSE AMERICAN: VNRX) ha nominato Timothy Still come Presidente del suo consiglio di amministrazione, a partire dal 6 novembre 2024. Still porta con sé oltre 35 anni di esperienza nella diagnostica medica, nei dispositivi e nella salute digitale. In precedenza ha ricoperto il ruolo di Presidente e CEO di Sense Biodetection e ha avuto posizioni di leadership in diverse aziende di tecnologia medica. Il suo ruolo più recente è stato presso TSTILL Enterprises come Presidente e CEO, oltre a essere Partner Operativo con REVIVAL Healthcare. Still ha conseguito un MBA presso USC e una laurea triennale presso UC Davis. La nomina avviene in un momento che l'azienda descrive come cruciale per lo sviluppo della tecnologia epigenetica per la rilevazione e il monitoraggio delle malattie.
VolitionRx (NYSE AMERICAN: VNRX) ha nombrado a Timothy Still como Presidente de su junta directiva, efectivo a partir del 6 de noviembre de 2024. Still aporta más de 35 años de experiencia en diagnóstico médico, dispositivos y salud digital. Anteriormente se desempeñó como Presidente y CEO de Sense Biodetection y ocupó puestos de liderazgo en varias empresas de tecnología médica. Su rol más reciente fue en TSTILL Enterprises como Presidente y CEO, al tiempo que también ejerce como Socio Operativo en REVIVAL Healthcare. Still tiene un MBA de USC y una licenciatura de UC Davis. La nombramiento se produce en un momento que la empresa describe como crucial para el desarrollo de la tecnología epigenética para la detección y el monitoreo de enfermedades.
VolitionRx (NYSE AMERICAN: VNRX)는 Timothy Still을 이사회의 의장으로 임명했다고 발표했으며, 이는 2024년 11월 6일부터 효력이 발생합니다. Still은 의료 진단, 장비 및 디지털 헬스 분야에서 35년 이상의 경험을 쌓아왔습니다. 그는 이전에 Sense Biodetection의 사장 및 CEO로 재직했으며 여러 의료 기술 회사에서 리더십 직책을 맡았습니다. 그의 최근 역할은 TSTILL Enterprises의 의장 및 CEO였으며, REVIVAL Healthcare의 운영 파트너로도 활동하고 있습니다. Still은 USC에서 MBA를, UC Davis에서 학사 학위를 취득했습니다. 이번 임명은 질병 탐지 및 모니터링을 위한 에피제네틱 기술 개발에 있어 회사가 결정적인 시점이라고 설명하는 때에 이루어졌습니다.
VolitionRx (NYSE AMERICAN: VNRX) a nommé Timothy Still au poste de Président de son conseil d'administration, à compter du 6 novembre 2024. Still apporte plus de 35 ans d'expérience dans le domaine des diagnostics médicaux, des dispositifs et de la santé numérique. Il a précédemment été Président et CEO de Sense Biodetection et a occupé des postes de direction au sein de plusieurs entreprises de technologie médicale. Son dernier rôle était chez TSTILL Enterprises en tant que Président et CEO, tout en exerçant également en tant que Partenaire Opérationnel chez REVIVAL Healthcare. Still possède un MBA de l'USC et une licence de l'UC Davis. Cette nomination intervient à un moment que l'entreprise décrit comme crucial pour le développement de sa technologie épigénétique destinée à la détection et à la surveillance des maladies.
VolitionRx (NYSE AMERICAN: VNRX) hat Timothy Still zum Vorsitzenden seines Vorstands ernannt, mit Wirkung zum 6. November 2024. Still bringt über 35 Jahre Erfahrung im Bereich medizinische Diagnostik, Geräte und digitale Gesundheit mit. Zuvor war er Präsident und CEO von Sense Biodetection und hatte Führungspositionen in verschiedenen Medizintechnikunternehmen inne. Seine letzte Position war bei TSTILL Enterprises als Vorsitzender und CEO, während er auch als Operating Partner bei REVIVAL Healthcare tätig war. Still hat einen MBA von der USC und einen Bachelor-Abschluss von der UC Davis. Die Ernennung erfolgt zu einem Zeitpunkt, den das Unternehmen als entscheidend für die Entwicklung seiner epigenetischen Technologie zur Krankheitsdiagnose und -überwachung beschreibt.
- Appointment of experienced chairman with 35+ years in medical diagnostics sector
- New chairman has successful track record in building commercial viability
- Previous experience includes multiple successful company acquisitions
- Strong expertise in implementing commercial and business development strategies
- None.
Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. Tim has been directly responsible for building the commercial viability at his previous companies, many through to acquisition.
His most recent operating role was President and CEO of Sense Biodetection. Early in 2023, Sense Bio merged with Sherlock Biosciences to create a leading point of care diagnostics company serving the consumer diagnostics market. Prior to Sense Biodetection, Mr. Still has been a CEO and/or a board member at numerous medical technology companies: Myoscience, MDx Health, Gold Standard Diagnostics (Executive Chairman), Global Kinetics, Xagenic and Accumetrics. Earlier in his career, Tim also held senior leadership roles at HemoSense, Cholestech, and Boehringer Mannheim/Roche.
Mr. Still has a master's degree in business administration (Dean's Scholar) from the University of
Commenting on his appointment, Timothy Still said:
"I am excited to join Volition at such a pivotal time in the company's journey. With its groundbreaking epigenetic technology, I believe Volition has the potential to significantly impact global healthcare by detecting, guiding treatment, and monitoring disease, to improve outcomes for people and animals worldwide. I look forward to working alongside the board and leadership team during this important next phase of growth at Volition."
Cameron Reynolds, President and Group Chief Executive Officer, added:
"We are delighted to welcome Tim as Chairman of the Board of Directors at Volition. He brings extensive experience in the diagnostic sector and has a proven track record of successfully guiding companies from the R&D phase to market readiness, ultimately driving commercial success. We look forward to benefiting from his strategic advice and leadership.
"I would like to thank Guy Innes, who has acted as our Interim Non-Executive Chair since the summer and continues to serve diligently on the Volition board."
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition's technology go to: www.volition.com.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the potential uses, benefits and effectiveness of Volition's Nu.Q® technology platform. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Photo - https://mma.prnewswire.com/media/2550489/Timothy_Still.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-appoints-timothy-i-still-as-chairman-302297781.html
SOURCE VolitionRx Limited
FAQ
Who is the new Chairman of VolitionRx (VNRX) appointed in November 2024?
What is Timothy Still's experience before joining VolitionRx (VNRX)?
Who did Timothy Still replace as Chairman at VolitionRx (VNRX)?